BMO's Kostas Biliouris: It will be challenging for the FDA to force a market withdrawal for Sarepta

• click to rate

  Posted by Two Blokes Mon at 5:00 PM - Filed in Stock - 2 views
  
  Kostas Biliouris, BMO Capital Markets biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest details on Sarepta after the company declined the FDA's request to halt shipments of its gene therapy.